• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病在大型前瞻性初级保健队列中的存在和严重程度。

Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.

机构信息

Centre for Liver Research, NIHR Liver Biomedical Research Unit, University of Birmingham, UK.

出版信息

J Hepatol. 2012 Jan;56(1):234-40. doi: 10.1016/j.jhep.2011.03.020. Epub 2011 May 18.

DOI:10.1016/j.jhep.2011.03.020
PMID:21703178
Abstract

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in primary care, but there are no data defining its contribution nor reporting the range of NAFLD severity in this setting. This study seeks to calculate the range of disease severity of NAFLD in a primary care setting.

METHODS

Adult patients with incidental abnormal LFTs, in the absence of a previous history, or current symptoms/signs of liver disease were prospectively recruited from eight primary care practices in Birmingham. NAFLD was diagnosed as fatty liver on ultrasound, negative serological liver aetiology screen, and alcohol consumption ≤30 and ≤20 g/day in males and females, respectively. The NAFLD Fibrosis Score (NFS) was calculated to determine the presence or absence of advanced liver fibrosis in subjects identified with NAFLD.

RESULTS

Data from 1118 adult patients were analysed. The cause of abnormal LFTs was identified in 55% (614/1118) of subjects, with NAFLD (26.4%; 295/1118) and alcohol excess (25.3%; 282/1118) accounting for the majority. A high NFS (>0.676) suggesting the presence of advanced liver fibrosis was found in 7.6% of NAFLD subjects, whereas 57.2% of NAFLD patients had a low NFS (<-1.455) allowing advanced fibrosis to be confidently excluded.

CONCLUSIONS

NAFLD is the commonest cause of incidental LFT abnormalities in primary care (26.4%), of whom 7.6% have advanced fibrosis as calculated by the NFS. This study is the first of its kind to highlight the burden of NAFLD in primary care and provide data on disease severity in this setting.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)是基层医疗中导致肝功能异常的常见原因,但目前尚无数据定义其在这种情况下的贡献,也没有报告其严重程度的范围。本研究旨在计算基层医疗环境中 NAFLD 的疾病严重程度范围。

方法

从伯明翰的 8 个基层医疗机构前瞻性招募了肝功能异常的成年患者(无既往病史或当前肝病的症状/体征)。NAFLD 通过超声诊断为脂肪肝,阴性血清肝脏病因学筛查,且男性和女性的酒精摄入量分别≤30 克/天和≤20 克/天。计算非酒精性脂肪性肝病纤维化评分(NFS)以确定患有 NAFLD 的患者是否存在或不存在晚期肝纤维化。

结果

对 1118 名成年患者的数据进行了分析。在 55%(614/1118)的患者中明确了肝功能异常的原因,其中非酒精性脂肪性肝病(26.4%;295/1118)和酒精过量(25.3%;282/1118)占多数。在 NAFLD 患者中,有 7.6%的 NFS 较高(>0.676)提示存在晚期肝纤维化,而 57.2%的 NAFLD 患者的 NFS 较低(<-1.455)可以明确排除晚期纤维化。

结论

NAFLD 是基层医疗中肝功能异常的最常见原因(26.4%),其中根据 NFS 计算有 7.6%的患者存在晚期纤维化。这项研究首次强调了 NAFLD 在基层医疗中的负担,并提供了该环境下疾病严重程度的数据。

相似文献

1
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.非酒精性脂肪性肝病在大型前瞻性初级保健队列中的存在和严重程度。
J Hepatol. 2012 Jan;56(1):234-40. doi: 10.1016/j.jhep.2011.03.020. Epub 2011 May 18.
2
NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.非酒精性脂肪性肝病纤维化评分:用于预测非酒精性脂肪性肝病患者死亡和肝脏并发症的预后指标。
World J Gastroenterol. 2013 Feb 28;19(8):1219-29. doi: 10.3748/wjg.v19.i8.1219.
3
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.美国非酒精性脂肪性肝病成人患者中无创性纤维化标志物与死亡率之间的关系。
Hepatology. 2013 Apr;57(4):1357-65. doi: 10.1002/hep.26156. Epub 2013 Jan 25.
4
Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease.非酒精性脂肪性肝病中国患者中简单无创性肝纤维化检测的表现不佳。
J Dig Dis. 2012 Nov;13(11):588-95. doi: 10.1111/j.1751-2980.2012.00631.x.
5
High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.非酒精性脂肪性肝病纤维化评分高可预测颈动脉斑块形成:基于中国常规健康检查数据的回顾性队列研究。
Ann Med. 2021 Dec;53(1):1621-1631. doi: 10.1080/07853890.2021.1974081.
6
Advanced liver fibrosis and the metabolic syndrome in a primary care setting.基层医疗环境中的进展性肝纤维化与代谢综合征。
Diabetes Metab Res Rev. 2021 Nov;37(8):e3452. doi: 10.1002/dmrr.3452. Epub 2021 Apr 9.
7
Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population.队列研究非酒精性脂肪性肝病、NAFLD 纤维化评分与韩国人群中糖尿病发病风险的关系。
Am J Gastroenterol. 2013 Dec;108(12):1861-8. doi: 10.1038/ajg.2013.349. Epub 2013 Oct 8.
8
Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者初级保健中纤维化风险评估的确认差距。
Dig Dis Sci. 2023 Jul;68(7):2946-2953. doi: 10.1007/s10620-023-07959-5. Epub 2023 May 16.
9
Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.非酒精性脂肪性肝病(NAFLD)纤维化评分可预测中国NAFLD患者6.6年的总死亡率。
Clin Exp Pharmacol Physiol. 2014 Sep;41(9):643-9. doi: 10.1111/1440-1681.12260.
10
A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.一种新型两步法,结合 NAFLD 纤维化评分和肝脏硬度测量,用于预测晚期纤维化。
Hepatol Int. 2015 Oct;9(4):594-602. doi: 10.1007/s12072-014-9596-7. Epub 2014 Dec 6.

引用本文的文献

1
Emerging role of natural bioactive compounds in navigating the future of liver disease.天然生物活性化合物在引领肝病未来发展中的新作用。
ILIVER. 2024 Dec 13;4(1):100140. doi: 10.1016/j.iliver.2024.100140. eCollection 2025 Mar.
2
Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S.通过IV型胶原7S预测代谢功能障碍相关脂肪性肝病中的晚期纤维化
Gastro Hep Adv. 2025 Mar 28;4(7):100668. doi: 10.1016/j.gastha.2025.100668. eCollection 2025.
3
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.
亚太肝脏研究协会代谢功能障碍相关脂肪性肝病诊断和管理临床实践指南
Hepatol Int. 2025 Apr;19(2):261-301. doi: 10.1007/s12072-024-10774-3. Epub 2025 Feb 27.
4
Liver diseases: epidemiology, causes, trends and predictions.肝脏疾病:流行病学、病因、趋势及预测
Signal Transduct Target Ther. 2025 Feb 5;10(1):33. doi: 10.1038/s41392-024-02072-z.
5
Approach to Abnormal Liver Biochemistries in the Primary Care Setting.基层医疗环境中异常肝脏生化指标的处理方法
Cureus. 2024 Mar 20;16(3):e56541. doi: 10.7759/cureus.56541. eCollection 2024 Mar.
6
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎:患者及医生视角
J Clin Med. 2023 Sep 26;12(19):6216. doi: 10.3390/jcm12196216.
7
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control study.通过转化性安全生物标志物管道(TransBioLine)联盟开发药物性肝损伤新型安全生物标志物的研究设计:一项巢式病例对照研究的研究方案
Diagn Progn Res. 2023 Sep 12;7(1):18. doi: 10.1186/s41512-023-00155-z.
8
Effect of bariatric surgery on NAFLD/NASH: a single-centre observational prospective cohort study.减重手术对非酒精性脂肪性肝病/非酒精性脂肪性肝炎的影响:一项单中心观察性前瞻性队列研究。
BMJ Open. 2023 Jul 3;13(7):e070431. doi: 10.1136/bmjopen-2022-070431.
9
Lower alanine aminotransferase levels are associated with increased all-cause and cardiovascular mortality in nonalcoholic fatty liver patients.较低的丙氨酸转氨酶水平与非酒精性脂肪肝患者全因死亡率和心血管死亡率升高相关。
World J Hepatol. 2023 Jun 27;15(6):813-825. doi: 10.4254/wjh.v15.i6.813.
10
Identifying Patients with Nonalcoholic Fatty Liver Disease in Primary Care: How and for What Benefit?在初级保健中识别非酒精性脂肪性肝病患者:方法及益处何在?
J Clin Med. 2023 Jun 12;12(12):4001. doi: 10.3390/jcm12124001.